fluoxymesterone + tamoxifen

Fluoxymesterone + tamoxifen is a combination of two small molecule drugs used in the hormonal treatment of breast cancer, particularly in postmenopausal women with metastatic disease. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts primarily as an antagonist of the estrogen receptor in breast tissue, thereby inhibiting estrogen-driven tumor growth. Fluoxymesterone is an androgenic anabolic steroid that exerts antitumor effects by counteracting estrogen activity and possibly through direct cytotoxic effects on hormone-sensitive tumors. Clinical studies have shown that this combination can improve response rates and time to disease progression compared to tamoxifen alone, especially in elderly women with higher levels of estrogen receptor expression[1][2][3].